๐ฐ Nasdaq Jspr News
Nasdaq Jspr News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Jspr. Real-time updates on events, politics, business and more.
April 19, 2024
Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) and Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk. Profitability This table compares Jasper Therapeutics […]
April 5, 2024
Investment analysts at Evercore ISI assumed coverage on shares of Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) in a note issued to investors on Wednesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $65.00 price target on the stock. Evercore ISI’s price target would indicate a potential upside of 136.02% from the stock’s […]
February 15, 2024
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 276,200 shares, a growth of 43.5% from the January 15th total of 192,500 shares. Based on an average daily volume of 109,400 shares, […]
February 2, 2024
REDWOOD CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (โJasperโ), a biotechnology company focused on...
January 12, 2024
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 184,300 shares, a decrease of 90.4% from the December 15th total of 1,910,000 shares. Currently, 2.3% of the shares of the company are […]
January 5, 2024
- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively - Patient enrollment in Phase...
October 16, 2023
Cantor Fitzgerald restated their overweight rating on shares of Jasper Therapeutics (NASDAQ:JSPR – Free Report) in a report issued on Thursday, Benzinga reports. They currently have a $6.00 price target on the stock. JSPR has been the topic of a number of other research reports. Credit Suisse Group restated an outperform rating and set a […]
September 21, 2023
Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) and Avalon GloboCare (NASDAQ:ALBT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation. Profitability This table compares Jasper Therapeutics and […]
August 14, 2023
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totalling 1,010,000 shares, a growth of 19.5% from the July 15th total of 845,500 shares. Based on an average daily volume of 304,400 shares, the short-interest ratio […]
June 16, 2023
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) saw a large decline in short interest in the month of May. As of May 31st, there was short interest totalling 861,500 shares, a decline of 18.0% from the May 15th total of 1,050,000 shares. Currently, 1.1% of the company’s shares are sold short. Based on an average […]